Bpifrance, the French national investment bank, has issued a grant valued at €10 million to Osivax SAS, a biotech company based in Lyon, to advance development of a broad-spectrum influenza vaccine candidate. The financing is part of a larger initiative by the French government to promote medical innovation and prepare for future pandemics and infectious diseases. Osivax will use the funds to prepare its vaccine, OVX836, for a Phase 2b field efficacy trial against a broad range of circulating influenza strains.
